Teleflex Awarded Agreements with Premier, Inc.
01 Junho 2023 - 7:30AM
Teleflex Incorporated (NYSE: TFX), a leading global provider of
medical technologies, today announced it was awarded two group
purchasing agreements with Premier, Inc. Effective July 1st, 2023,
the new agreements allow Premier members, at their discretion, to
take advantage of special pricing and terms pre-negotiated by
Premier for Teleflex’s Central Venous and Arterial Vascular Access
products. Premier has awarded Teleflex a national agreement for
Hemodynamic Monitoring Products and Accessories, a national
agreement for Central Venous Access, a Sole Source for AscenDrive
Central Venous Access, and a Sole Source for SURPASS Central Venous
Access.
“Teleflex strives to deliver vascular access
products that are designed to benefit both clinicians and patients,
while helping to protect against vascular access related
complications like infection and thrombosis,” said Lisa Kudlacz,
President and General Manager, Teleflex Vascular. “As the market
leader in both Central Venous Catheters and Arterial Access
Catheters1, we are pleased to continue to support Premier members
with these products.”
Teleflex, through its Arrow® CVC products, has been innovating
for more than four decades to help healthcare providers optimize
patient outcomes, minimize the risk of central line-associated
infections (CLABSI), and efficiently streamline insertion
procedures2-5. The group purchasing agreements include access to
Arrowg+ard Blue Plus® CVCs and Arrow® ErgoPack® Complete
Systems.
Antimicrobial Arrowg+ard Blue Plus® CVCs are the only
broad-spectrum antimicrobial CVCs that protect against both
gram-positive and gram-negative bacteria, fungi, and demonstrate a
67-100% reduction in CLABSI2-5. Combined with antimicrobial
Arrowg+ard Blue Plus® CVCs, Arrow® ErgoPack® Complete Systems are
designed to help make it easy to:
- Standardize vascular access across a system
- Maintain a high standard of patient care
- Control costs and risks from infections6
Arrow® ErgoPack® Complete Systems are designed to help
clinicians comply with third-party guideline recommendations7-10,
including:
- CDC Category 1A &1B Recommendations
- SHEA Guidelines
- INS Standards of Practice
- OSHA Bloodborne Pathogens Standard
Premier is a leading healthcare improvement company, uniting an
alliance of approximately 4,400 U.S. hospitals and 250,000 other
providers to transform healthcare. With integrated data and
analytics, collaboratives, supply chain solutions, and consulting
and other services, Premier enables better care and outcomes at a
lower cost.
About Teleflex IncorporatedTeleflex is a global
provider of medical technologies designed to improve the health and
quality of people’s lives. We apply purpose driven innovation – a
relentless pursuit of identifying unmet clinical needs – to benefit
patients and healthcare providers. Our portfolio is diverse, with
solutions in the fields of vascular access, interventional
cardiology and radiology, anesthesia, emergency medicine, surgical,
urology and respiratory care. Teleflex employees worldwide are
united in the understanding that what we do every day makes a
difference. For more information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, LMA®, Pilling®,
QuikClot®, Rüsch®, UroLift®, and Weck® – trusted brands united by a
common sense of purpose.
Forward-Looking StatementsAny statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which
may cause actual results or company actions to differ materially
from what is expressed or implied by these statements. These risks
and uncertainties are identified and described in more detail in
our filings with the Securities and Exchange Commission, including
our Annual Report on Form 10-K.
References
- IQVIA Data. Data based on 2022 Q4 Total Acute CVC market unit
share for Teleflex. 2022.
- Rupp ME, Lisco SJ, Lipsett PA, et al. Effect of a
Second-Generation Venous Catheter Impregnated with Chlorhexidine
and Silver Sulfadiazine of Central Catheter-Related Infections. Ann
Intern Medicine. 2005; 143: 570-80. Sponsored by Arrow
(Teleflex).
- Lorente L, Lecuona M, Jimenez A, et al. Chlorhexidine-silver
sulfadiazine-impregnated venous catheters save costs. American
Journal of Infection Control. 2014; 42: 321-4.
- Lorente L, Lecuona M, Jimenez A, et al. Cost/benefit analysis
of chlorhexidine-silver sulfadiazine-impregnated venous catheters
for femoral access. American Journal of Infection Control. 2014;
42: 1130-2.
- Lorente, L, et al. Chlorhexidine-silver
sulfadiazine-impregnated venous catheters are efficient even at
subclavian sites without tracheostomy. American journal of
infection control. 2016; 44(12): 1526-29. Zimlichman, E, et
al.
- Abouleish, YZ, Oldfield EC, Marik PE. Comparison of
central-line–associated bloodstream infections between central
venous catheters lined by combined chlorhexidine and silver
sulfadiazine versus silver ionotrophes alone: A before–after–before
retrospective study. Infection Control & Hospital Epidemiology
(2020): 1-3.
- O’Grady NP, Alexander M, Burns LA, et al. Guidelines for the
Prevention of Intravascular Catheter-Related Infections, 2011
(Revised 2017). 2. Atlanta, GA: Centers for Disease Control and
Prevention; 2017.
- Buetti, N., Marschall, J., Drees, M., Fakih, M., Hadaway, L.,
Maragakis, L., Mermel, L. (2022). Strategies to prevent central
line-associated bloodstream infections in acute-care hospitals:
2022 Update. Infection Control & Hospital Epidemiology, 1-17.
doi:10.1017/ice.2022.87.
- Gorski, Lisa A., et al. "Infusion therapy standards of
practice." Journal of Infusion Nursing, 44.1S (2021): S1-S224.
- Occupational Safety & Health Administration Regulations
(Standards – 29 CFR). Part 1910.1030: Bloodborne pathogens.
Occupational Safety & Health Administration Web site.
https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1030.
Accessed on February 12, 2020.
Rx onlyContraindication: The Arrowg+ard Blue Plus® CVC is
contraindicated for patients with known hypersensitivity to
chlorhexidine and silver sulfadiazine and/or sulfa drugs.
Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue Plus,
Deknatel, ErgoPack, LMA, Pilling, QuikClot, Rüsch, UroLift, and
Weck are trademarks or registered trademarks of Teleflex
Incorporated or its affiliates, in the U.S. and/or other countries.
All other trademarks are trademarks or registered trademarks of
their respective owners. © 2023 Teleflex Incorporated. All rights
reserved. MC-008941
Contact:Teleflex Incorporated:Lawrence
KeuschVice President, Investor Relations and Strategy
Development
investors.teleflex.com610-948-2836
Teleflex (NYSE:TFX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Teleflex (NYSE:TFX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024